Now we need more research to determine whether levels of these potential biomarkers predict which prostate cancers detected by screening might progress to become life-threatening.
A new study by researchers from the University of Bristol, presented at the National Cancer Research Institute (NCRI) conference today, has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease. The researchers, from the University's School of Social and Community Medicine , investigated levels of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in men whose cancer had been detected through PSA screening. They compared 2,686 men with prostate cancer with 2,766 men who didn?t have cancer and found that specific growth factors (IGF-II) and proteins (IGFBP-2 and IGFBP-3) were all linked to an increased risk of the disease. But they found there was no link between the best known growth factor (IGF-1) levels and a higher risk of prostate cancer. The growth factors - IGFs and IGFBPs - regulate normal growth and development of organs and tissues, especially during foetal development and childhood.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
